May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Comparison of Intraocular Pressure Lowering Efficacy of Fixed Combination Timolol–Dorzolamide versus Timolol Plus Latanoprost
Author Affiliations & Notes
  • G.C. Lee
    Ophthalmology, Wills Eye Hospital, Philadelphia, PA
  • L.J. Katz
    Ophthalmology, Wills Eye Hospital, Philadelphia, PA
  • J. Molineaux
    Ophthalmology, Wills Eye Hospital, Philadelphia, PA
  • J. Fontanarosa
    Ophthalmology, Wills Eye Hospital, Philadelphia, PA
  • W.C. Steinmann
    Ophthalmology, Wills Eye Hospital, Philadelphia, PA
  • Footnotes
    Commercial Relationships  G.C. Lee, None; L.J. Katz, None; J. Molineaux, None; J. Fontanarosa, None; W.C. Steinmann, None.
  • Footnotes
    Support  Merck and Co, INC
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3797. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G.C. Lee, L.J. Katz, J. Molineaux, J. Fontanarosa, W.C. Steinmann; Comparison of Intraocular Pressure Lowering Efficacy of Fixed Combination Timolol–Dorzolamide versus Timolol Plus Latanoprost . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3797.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare the effect of fixed combination timolol–dorzolamide to treatment with an unfixed combination of timolol and latanoprost. Methods: Patients diagnosed with primary open–angle, normal tension, and pseudoexfoliative glaucoma were prospectively screened. Age, gender, race, diagnosis, visual acuity, applanation tonometry, time of day and adverse effects of treatment were recorded by an examiner masked to treatment. A crossover study was conducted where all patients were started on timolol at the initial screening visit for a minimum of 4 weeks. After the 4 week treatment period, patients were randomized either to fixed combination timolol–dorzolamide––Group A––or the unfixed combination of timolol plus latanaprost––Group B. Patients were monitored for another minimum of 4 weeks and had intraocular pressures recorded. Then, all patients were started on timolol alone for a 4 week washout period. After the washout period, Group A was treated with timolol plus latanoprost and Group B with fixed combination timolol–dorzalamide. Patients had intraocular pressure recorded after 4 weeks of treatment. Results: Forty eight eyes of 29 patients were included. Mean baseline intraocular pressure for the fixed combination timolol–dorzolamide and for timolol plus latanoprost were not statistically different (17.5±4.3 mmHg, 17.3±4.0 mmHg, p=0.4). The mean change in the fixed combination timolol–dorzolamide was a decrease of 1.3±3.0 mmHg (p=0.004). The mean change in the unfixed combination of timolol plus latanoprost was a decrease of 1.3±2.8 mmHg (p=0.002). There was no statistical difference in the change in intraocular pressure between the two treatments with the fixed combination timolol–dorzolamide and the timolol plus latanoprost (p=1.0). Conclusions: Glaucoma patients treated with fixed combination timolol–dorzolamide and unfixed combination timolol plus latanoprost had equivalent decreases in intraocular pressure.

Keywords: intraocular pressure • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×